CAJ | 학술논문

目前肺癌的发病率和死亡率在中国城市中列居首位,静脉血栓栓塞症(venous thromboembolism,VTE)是恶性肿瘤患者常见的并发症,成为肿瘤患者的第2位死因.恶性肿瘤导致VTE发生的原因与凝血纤溶系统、血小板、血管内皮细胞等因素有关;另外,肿瘤本身及其相关治疗也增加了肺癌并发VTE的风险.2009年美国胸科协会及欧洲心脏协会发表的肿瘤患者VTE防治指南指出,抗凝治疗是肺癌合并VTE患者的基本治疗措施,但要注意出血风险.
목전폐암적발병솔화사망솔재중국성시중렬거수위,정맥혈전전새증(venous thromboembolism,VTE)시악성종류환자상견적병발증,성위종류환자적제2위사인.악성종류도치VTE발생적원인여응혈섬용계통、혈소판、혈관내피세포등인소유관;령외,종류본신급기상관치료야증가료폐암병발VTE적풍험.2009년미국흉과협회급구주심장협회발표적종류환자VTE방치지남지출,항응치료시폐암합병VTE환자적기본치료조시,단요주의출혈풍험.
At present, the incidence and mortality of lung cancer ranks the first in Chinese cities.Venous thromboembolism (VTE) is a common complication in patients with malignant tumors, which is the second cause of death in cancer patients. VTE caused by malignant tumors is related with coagulation and fibrinolysis system,platelets,vascular endothelial cells and other factors. In addition, the tumor itself and its related treatment also increase the risk of lung cancer complicating with VTE. The guidelines (2009) of American College of Chest Physicians and European Society of Cardiology recommend that anticoagulant therapy is the basic treatment for patients with lung cancer complicating with VTE,but the risk of bleeding should be paid attention to.